Home » ENDO PHARMACEUTICALS JULY OPTION IMPLIED VOLATILITY BID UP INTO 6/22/06 PDUFA

ENDO PHARMACEUTICALS JULY OPTION IMPLIED VOLATILITY BID UP INTO 6/22/06 PDUFA

June 1, 2006

Endo Pharmaceuticals researches, develops and markets both branded and generic pharmaceutical products for the treatment of pain and opioid analgesics. StreetInsider.com (http://www.streetinsider.com/news.php?id=917679&st=p)

KEYWORDS FDAnews Drug Daily Bulletin

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

ENDO PHARMACEUTICALS JULY OPTION IMPLIED VOLATILITY BID UP INTO 6/22/06 PDUFA

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

Cue Health’s COVID-19 Test Receives CE Mark

Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements